PR Newswire Clinical TrialsOriginal article
AMO Pharma Announces Update on Scientific Advice for Registrational Clinical Study of AMO-02 in Congenital Myotonic Dystrophy Type 1 Following Meetings with the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada
RegulatoryAMO-02Positive
AI Analysis
Summary
AMO Pharma announced it received regulatory guidance from the FDA, MHRA, and Health Canada on the design of its registrational study for AMO-02 in Congenital Myotonic Dystrophy Type 1, planning to use hospitalization as the primary outcome measure.
Clinical Trial Data
Phase
registrational
Outcome Details
FDA, MHRA, and Health Canada provided scientific advice for registrational clinical study design. Primary outcome measure will be hospitalization, with functional assessments as secondary endpoints.
Importance:5/10
Sentiment:
0.30
regulatory_guidancerare_diseasepediatric_indicationclinical_trial_designmulti_agency_meeting
Read the original article
Published by PR Newswire Clinical Trials on July 6, 2026 9:49 PM